Pharmalab India Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.21 Cr
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 34.13 Cr
- Satisfied Charges ₹ 76.06 Cr
- Revenue Growth 8.36%
- Profit Growth 86.28%
- Ebitda 92.88%
- Net Worth 32.11%
- Total Assets 6.91%
About Pharmalab India
Pharmalab India Private Limited. (PIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 25 January 2006 and has a history of 19 years and one month. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Pharmalab Process Equipments Private Limited. The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.21 Cr.
The company currently has active open charges totaling ₹34.13 Cr. The company has closed loans amounting to ₹76.06 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vishal Shah, Kunal Shah, Rashmikant Shah, and Four other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U29297MH2006PTC163141
- Company No.
163141
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jan 2006
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Pharmalab India Private Limited. offer?
Pharmalab India Private Limited. offers a wide range of products and services, including Autoclaves, Sterilizers & Incubators, Laboratory Autoclave & Sterilizers, Water Treatment & Purification Plant, Water Purification Plants, Dryers & Evaporators, Evaporator, Chemical Plants & Machinery, Distillation Units, Pollution Control Devices & Machines, Bag Filter.
Who are the key members and board of directors at Pharmalab India?
Board Members (7)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kunal Shah ![]() | Director | 09-Jan-2020 | Current |
Vishal Shah ![]() | Director | 09-Jan-2020 | Current |
Rashmikant Shah ![]() | Director | 25-Jan-2006 | Current |
Umesh Shah ![]() | Director | 22-Oct-2007 | Current |
Nitin Shah ![]() | Director | 25-Jan-2006 | Current |
Karnik Parikh ![]() | Director | 10-Jun-2008 | Current |
Financial Performance of Pharmalab India.
Pharmalab India Private Limited., for the financial year ended 2023, experienced modest growth in revenue, with a 8.36% increase. The company also saw a substantial improvement in profitability, with a 86.28% increase in profit. The company's net worth Soared by an impressive increase of 32.11%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmalab India?
In 2023, Pharmalab India had a promoter holding of 46.13% and a public holding of 53.88%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹34.13 Cr
₹76.06 Cr
Charges Breakdown by Lending Institutions
- Others : 33.72 Cr
- Axis Bank Limited : 0.26 Cr
- Hdfc Bank Limited : 0.12 Cr
- Dena Bank : 0.03 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
29 Mar 2024 | Others | ₹6.40 Cr | Open |
31 Aug 2023 | Others | ₹2.00 Cr | Open |
12 Jun 2023 | Others | ₹1.00 Cr | Open |
09 Mar 2023 | Axis Bank Limited | ₹2.60 M | Open |
31 Dec 2022 | Others | ₹1.60 M | Open |
How Many Employees Work at Pharmalab India?
Pharmalab India has a workforce of 52 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Pharmalab India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmalab India's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.